Highly efficient selection of epitope specific antibody through competitive yeast display library sorting

mAbs

Volumn 5, Issue 4, 2013, Pages 533-539

  Puri, Vinita ^a   Streaker, Emily ^a,b   Prabakaran, Ponraj ^a,b   Zhu, Zhongyu ^a   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Competitive sorting; Dengue virus; Epitope specific targeting; Human antibody library; Yeast display antibody library

Indexed keywords

ANTIBODY; EPITOPE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VIRUS FUSION PROTEIN;

ANTIBODY LIBRARY; ARTICLE; BIOTINYLATION; DENGUE VIRUS; EPITOPE MAPPING; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; YEAST;

COMPETITIVE SORTING; DENGUE VIRUS; EPITOPE SPECIFIC TARGETING; HUMAN ANTIBODY LIBRARY; YEAST DISPLAY ANTIBODY LIBRARY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; DENGUE VIRUS; EPITOPES; HUMANS; NEOPLASM PROTEINS; PEPTIDE LIBRARY; SACCHAROMYCES CEREVISIAE; VIRAL ENVELOPE PROTEINS;

EID: 84880101283     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.25211     Document Type: Article

References (28)

1. Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends - is a paradigm change coming soon? [xiii.]. Methods Mol Biol 2009; 525:1-27, xiii; PMID:19252861; http://dx.doi.org/10.1007/978-1-59745-554-1-1
2. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767-74; PMID:20811384; http://dx.doi.org/10.1038/nrd3229
3. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23:1105-16; PMID:16151404; http://dx.doi.org/10.1038/ nbt1126
4. Groves MA, Osbourn JK. Applications of ribosome display to antibody drug discovery. Expert Opin Biol Ther 2005; 5:125-35; PMID:15709915; http://dx.doi.org/10.1517/14712598.5.1.125
5. Ladner RC, Sato AK, Gorzelany J, de Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 2004; 9:525-9; PMID:15183160; http://dx.doi.org/10.1016/S1359-6446(04)03104-6
6. Brekke OH, Løset GA. New technologies in therapeutic antibody development. Curr Opin Pharmacol 2003; 3:544-50; PMID:14559101; http://dx.doi.org/10.1016/j.coph.2003.05.002
7. Osbourn J, Jermutus L, Duncan A. Current methods for the generation of human antibodies for the treatment of autoimmune diseases. Drug Discov Today 2003; 8:845-51; PMID:12963321; http://dx.doi.org/10.1016/S1359-6446(03)02803-4
8. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997; 15:553-7; PMID:9181578; http://dx.doi.org/10.1038/nbt0697-553
9. Shibasaki S, Ueda M. Development of yeast molecular display systems focused on therapeutic proteins, enzymes, and foods: functional analysis of proteins and its application to bioconversion. Recent Pat Biotechnol 2010; 4:198-213; PMID:21171957; http://dx.doi.org/10.2174/187220810793611545
10. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007; 5:518-28; PMID:17558424; http://dx.doi.org/10.1038/nrmicro1690
11. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 2010; 6:e1000823; PMID:20369024; http://dx.doi.org/10.1371/journal.ppat.1000823
12. Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillén G. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 2010; 9:137-47; PMID:20109025; http://dx.doi.org/10.1586/erv.09.139
13. Gromowski GD, Barrett ND, Barrett AD. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 2008; 82:8828-37; PMID:18562544; http://dx.doi.org/10.1128/JVI. 00606-08
14. Rajamanonmani R, Nkenfou C, Clancy P, Yau YH, Shochat SG, Sukupolvi-Petty S, et al. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol 2009; 90:799-809; PMID:19264660; http://dx.doi.org/10. 1099/vir.0.006874-0
15. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 2010; 84:9227-39; PMID:20592088; http://dx.doi.org/10.1128/JVI.01087-10
16. Zhu Z, Dimitrov DS. Construction of a large naïve human phage-displayed Fab library through one-step cloning. [xv.]. Methods Mol Biol 2009; 525:129-42, xv; PMID:19252833; http://dx.doi.org/10.1007/978-1-59745-554- 1-6
17. Chen W, Zhu Z, Liao H, Quinnan GV Jr., Broder CC, Haynes BF, et al. Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins. Viruses 2010; 2:547-65; PMID:21755021; http://dx.doi.org/10.3390/v2020547
18. Giudicelli V, Brochet X, Lefranc MP. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb Protoc; 2011:695-715.
19. Zhang MY, Choudhry V, Sidorov IA, Tenev V, Vu BK, Choudhary A, et al. Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods 2006; 317:21-30; PMID:17078964; http://dx.doi.org/10.1016/j.jim.2006.09.016
20. Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci U S A 2009; 106:20216-21; PMID:19875695; http://dx.doi.org/10.1073/pnas.0909775106
21. Arnaout R, Lee W, Cahill P, Honan T, Sparrow T, Weiand M, et al. High-resolution description of antibody heavy-chain repertoires in humans. PLoS One 2011; 6:e22365; PMID:21829618; http://dx.doi.org/10.1371/journal.pone. 0022365
22. Kita Y, Tseng J, Horan T, Wen J, Philo J, Chang D, et al. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies. Biochem Biophys Res Commun 1996; 226:59-69; PMID:8806592; http://dx.doi.org/10.1006/bbrc.1996.1311
23. Yip YL, Smith G, Koch J, Dübel S, Ward RL. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J Immunol 2001; 166:5271-8; PMID:11290813
24. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011; 25:13-25; PMID:21090841; http://dx.doi.org/10.2165/11539590-000000000-00000
25. Bornstein GG, Quéva C, Tabrizi M, van Abbema A, Chavez C, Wang P, et al. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs 2010; 28:561-74; PMID:19626278; http://dx.doi.org/10.1007/s10637-009-9291-z
26. Reichert JM. Next Generation and Biosimilar Monoclonal Antibodies: Essential Considerations Towards Regulatory Acceptance in Europe; February 3-4, 2011; Freiburg, Germany. MAbs; 3.
27. Ledford H. 'Biosimilar' drugs poised to penetrate market. Nature 2010; 468:18-9; PMID:21048737; http://dx.doi.org/10.1038/468018a
28. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 2008; 15:312-7; PMID:18264114; http://dx.doi.org/10.1038/nsmb.1382